J&J’s Spravato Wins FDA Approval, Stands as a Game-Changer for Mental Health Care
New Brunswick, NJ January 21, 2025 Johnson & Johnson (NYSE:JNJ) has finally got its breakthrough depression treatment, Spravato (esketamine), approved by the U.S. FDA (Food and Drug Administration) as thefirst and only standalone…